title: Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
abstract: A series of pyridine-based derivatives of the clinically successful Ru(III)-based complexes indazolium [trans-RuCl4(1H-indazole)2] (KP1019) and sodium [trans-RuCl4(1H-indazole)2] (KP1339) have been synthesized to probe the effect of hydrophobic interactions with human serum albumin (hsA) on anticancer activity. The solution behavior and protein interactions of the new compounds were characterized by using electron paramagnetic resonance (EPR) and UV/Vis spectroscopy. These studies have revealed that incorporation of hydrophobic substituents at the 4'-position of the axial pyridine ligand stabilizes non-coordinate interactions with hsA. As a consequence, direct coordination to the protein is inhibited, which is expected to increase the bioavailability of the complexes, thus potentially leading to improved anticancer activity. By using this approach, the lifetimes of hydrophobic protein interactions were extended from 2 h for the unsubstituted pyridine complex, to more than 24 h for several derivatives. Free complexes were tested for their anticancer activity against the SW480 human colon carcinoma cell line, exhibiting low cytotoxicity. Pre-treatment with hsA improved the solubility of every compound and led to some changes in activity. Particularly notable was the difference in activity between the methyl- and dibenzyl-functionalized complexes. The former shows reduced activity after incubation with hsA, indicating reduced bioavailability due to protein coordination. The latter exhibits little activity on its own but, following treatment with hsA, exhibited significant cytotoxicity, which is consistent with its ability to form non-coordinate interactions with the protein. Overall, our studies demonstrate that non-coordinate interactions with hsA are a viable target for enhancing the activity of Ru(III)-based complexes in vivo.
authors.affiliation: Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6 (Canada), Fax: (+1) 778-782-3765.
authors.forename: Michael I
authors.initials: MI
authors.lastname: Webb
authors.forename: Boris
authors.initials: B
authors.lastname: Wu
authors.forename: Thalia
authors.initials: T
authors.lastname: Jang
authors.forename: Ryan A
authors.initials: RA
authors.lastname: Chard
authors.forename: Edwin W Y
authors.initials: EW
authors.lastname: Wong
authors.forename: May Q
authors.initials: MQ
authors.lastname: Wong
authors.forename: Donald T T
authors.initials: DT
authors.lastname: Yapp
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Walsby
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003110:Colonic Neoplasms / Q000737:chemistry* / Q000188:drug therapy*; D018360:Crystallography, X-Ray; D004578:Electron Spin Resonance Spectroscopy; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D007191:Indazoles / Q000737:chemistry* / Q000494:pharmacology*; D008024:Ligands; D015394:Molecular Structure; D009942:Organometallic Compounds / Q000737:chemistry* / Q000494:pharmacology*; D012428:Ruthenium / Q000737:chemistry*; D017975:Ruthenium Compounds / Q000737:chemistry* / Q000494:pharmacology*; D012709:Serum Albumin / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; D008024:Ligands; D009942:Organometallic Compounds; D017975:Ruthenium Compounds; D012709:Serum Albumin; C499292:indazolium trans-(tetrachlorobis(1H-indazole)ruthenate (III)); D012428:Ruthenium
keywords: albumin; cytotoxicity; hydrophobic interactions; ligand design; ruthenium